Administration of high doses of recombinant human erythropoietin to patients with β-thalassemia intermedia: A preliminary trial

European Journal of Haematology

Volumn 58, Issue 1, 1997, Pages 22-25

  Bourantas, K ^a,b   Economou, G ^a   Georgiou, J ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b NONE   (Greece)

Author keywords

erythropoietin; thalassemia intermedia

Indexed keywords

FERROUS SULFATE; FOLIC ACID; RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031024827     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1997.tb01405.x     Document Type: Article

References (16)

1. Wintrobe's Clinical Hematology. Philadelphia: Lea and Febiger, 1993: 1106-1123.
2. CAMASCELLA C, SAGLIO G, PICH PG, et al. Thoracic extra-medullary hematopoiesis in thalassemia intermedia during adult life: a report of 9 cases. Haematologica 1981:66:613-626.
3. OLIVIERI NF, MACKINNON J, COLLONS AF, SHER GD. Long-term treatment with recombinant human erythropoietin in patients with thalassemia: reduction in requirement for transfusion and chelation therapy. Sickle cell disease and thalassemia. In: BEUZARD Y, LUBIN B, RESA J, eds. New trends in therapy, Vol. 234. Paris: INSERM/John Libbey Eurotext Ltd, 1995: 203-205.
4. KAZAZIAN JR HH. The thalassemia syndromes: molecular basis and prenatal diagnosis in 1990. Semin Hematol 1990: 27: 209-228.
5. 0-thalassemia. Eur J Haematol 1995: 54: 101-105.
6. SPYRIDAKIS S, KARAGIORGA-LAGANA M, VOSKAKI I, EFTHIMOU H, KARAKLIS A. A simple index for initiating transfusion treatment in beta thalassemia intermedia. Br J Haematol 1987: 67: 479-483.
7. SPIVAK JL. The mechanism of action of erythropoietin. Int J Cell Cloning 1986: 4: 139.
8. RACHMILEWITZ EA, GOLDFARB A, DOVER G. Administration of erythropoietin to patients with β-thalassemia intermedia: a preliminary trial. Blood 1991: 78: 1145-1147.
9. OLIVIERI NF, PERRINE S, DOVER GJ, SHERIDAN B, ESSENTINE DL, NAGEL RL. The recombinant human erythropoietin: three patients with thalassemia intermedia. Blood 1992: 80: 3258-3260.
10. SUTTON M, BOUHASSIRA EE, NAGEL RL. Polymerase chain reaction amplification applied to the determination of β-like globin gene cluster haplotypes. Am J Hematol 1989: 32: 66-69.
11. RHYNER K, EGLI F, NIEMOLLER M, WIECZORAK A, GREMINGER P, VETTER W. Serum erythropoietin levels in various disease. Nephron 1989: 51 (Suppl 1): 3-41.
12. KONIJN AM, LEVY R, LINK G, HERSHKO C. A rapid and sensitive ELISA for serum ferritin employing a fluorogenic substance. J Immunol Methods 1992: 54: 297-312.
13. ALESSI M, LONGO G, DIMARTINO G, CACCIOLA E, SORTING G. Serum erythropoietin levels in beta thalassemia. Ann N Y Acad Sci 1990: 612: 534-537.
14. SHERWOOD JB, GOLDWASSER E, CHILCOTE R, CARMICHAEL LD, NAGEL RL. Sickle cell anemia patients have a low erythropoietin level for their degree of anemia. Blood 1986: 67: 46-49.
15. CAO A, DORE F, LIBERATO NL, GUARNONE R, BAROSI G. Serum erythropoietin and erythropoiesis in high and low fetal hemoglobin β-thalassemia intermedia patients. Blood 1994: 83: 561-565.
16. AL-KHATTI A, VEITH RW, PAPAYANOPOULOU T, FRITSCH EF, GOLDWASSER E, STAMATOYANNOPOULOS G. Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons. N Engl J Med 1987: 317: 415-420.